ERSPC eesnäärmevähi riski kalkulaator: väljatöötamisest kasutamiseni kliinilises praktikas
Väljatöötamine
Rakendamine
Uued omadused
Valideerimine
Kasutamine kliinilises praktikas
ERSPC: sõeluuringuga seotud publitseeritud leiud (veel)
2010-2011
Guazzoni, G., Nava, L., Lazzeri, M., et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: Results of a prospective study in a clinical setting. Eur Urol, 2011, 60(2), 214−222.
Vickers, A. J., Cronin, A. M., Roobol, M. J., Savage, C. J., Peltola, M., Pettersson, K., et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res, 2010, 16(12): 3232−3239.
Bangma, C. H., van Schaik, R. H., Blijenberg, B. G., Roobol, M. J., Lilja, H., Stenman, U. H. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer. Eur J Cancer, 2010, 46(17), 3109−3119.
Roobol, M. J., Steyerberg, E. W., Kranse, R., Wolters, T., van den Bergh, R. C., Bangma, C. H., et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010, 57(1), 79−85.
Jansen, F. H., van Schaik, R. H. N., Kurstjens, J., Horninger, W., Klocker, H., Bektic, J., Wildhagen, M. F., Roobol, M. J., Bangma, C. H., Georg, B. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol, 2010, 57(6), 921–927.
(veel)
Vajutage siia, et